Announcements Trials

Browse Landscape

Phase

Phase 2 7 Phase 3 3 Phase 1/2 3 Phase NA 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10 Sarcoma 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Neoplasms 2 Inflammatory Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Patients With Advanced or Metastatic Solid Tumors 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neutropenia 1 Liver Neoplasms 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Bile Duct Neoplasms 1

Interventions

Carboplatin 19 Paclitaxel 18 Fluorouracil 16 Cisplatin 16 pembrolizumab 15 Radiotherapy 14 Oxaliplatin 12 Irinotecan 12 Capecitabine 12 Cyclophosphamide 10 Radiation 8 Leucovorin 8 Docetaxel 8 fludarabine 6 Taxes 6 Gemcitabine 6 Trastuzumab 5 fludarabine phosphate 4 aldesleukin 4 LY6K protein, human 4 Fluorodeoxyglucose F18 4 Erlotinib Hydrochloride 4 Bevacizumab 4 spartalizumab 3 Surgical Procedures, Operative 3 S 1 (combination) 3 Pemetrexed 3 Nivolumab 3 Drug Therapy 3 zimberelimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Esophageal Neoplasms × Epirubicin × Clear all

NCT01386346 2018-12-12

VEOX

Weill Medical College of Cornell University

Phase 1 Completed

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡